newsfilter
← Latest News
GlobeNewswire·

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

  • Rani Therapeutics Holdings, Inc. appointed Dr. Sara Kenkare-Mitra as a Strategic Advisor on April 09, 2026.
  • Dr. Kenkare-Mitra brings nearly three decades of experience in biologics & small molecule drug discovery, development, & global regulatory approvals.
  • She will provide strategic counsel on platform strategy, therapeutic focus, candidate selection, & development prioritization to maximize clinical success.
  • Her appointment follows encouraging preclinical data for oral semaglutide & other RaniPill® programs.
  • Previously, she served as President & Head of R&D at Alector & spent over 20 years at Genentech, contributing to the approval of therapies including Xolair®, Tarceva®, Avastin®, & Ocrevus®.
  • Dr. Kenkare-Mitra is an elected member of the National Academy of Medicine, a Fellow of the American Association for the Advancement of Science, & holds a Ph.D. from the University of California, San Francisco.
  • Rani Therapeutics develops the RaniPill® capsule, a patented platform designed to enable oral administration of biologics & replace subcutaneous injections or intravenous infusions.